Kevan L. Hartshorn, MD
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology Section

MD, Albert Einstein College of Medicine
MA, Williams College

Expertise includes: Innate immunity to respiratory infection; Neutrophil Biology; Influenza Virus; Gastrointestinal cancer.

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Division of Graduate Medical Sciences

Active Staff Privileges
Boston Medical Center
Hematology & Medical Oncology Section

2010-2010 Boston Magazine: Selected as one of Boston's Top Doctors for 2010

A Randomized, Double-blind, Phase II Study of RAD001 10 mg/d plus Best Supportive Care versus Placebeo plus Best Supportive Care in the Treatment of Patients with Advanced Pancreatic Neuroendocri
04/04/2008 - 04/30/2011 (PI)
Novartis Pharmaceuticals Corporation

A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care vs placebo, plus best best supportive care in patients with advanced gastric cance
03/16/2010 - 02/28/2011 (PI)
Novartis Pharmaceuticals Corporation

A Phase II, Multi-center, Open-label Trial to Evaluate the Efficacy and Safety of DAVANAT in Combination with 5-Fluorouracil when Administered as First Line Chemotherapy in Patients Advanced Bili
07/05/2007 - 07/04/2010 (PI)
Pro-Pharmaceuticals, Inc.

A Randomized, Open-Label Trial Comparing Two Avastin (bevacizumab)- Based Treatment Regimens for the First-Line Treatment of Metastatic Colorectal Cancer
05/17/2006 - 12/31/2009 (PI)
Genentech, Inc.

Enhancing Collectin Mediated Host Defense
04/01/1998 - 03/31/2003 (PI)
NIH/National Heart, Lung, and Blood Institute
5 R01 HL58910 04

An Open Label, Randomized, Controlled, Phase III, Multicenter, Clinical Trial of PN401 with HighDose 5-Fluoraouracil (5FU) vs. Gemcitabine for Treatment of Patients with Advanced Pancreatic Cancer
12/01/2001 - 11/30/2002 (PI)

Enhancing Collectin Mediated Defense Against Influenza
07/01/2016 - 06/30/2019 (PI)

A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib of Placebo in Comb…
01/15/2015 - 01/31/2018 (PI)
Incyte Corporation

The JANUS 1 Study
08/26/2015 - 08/31/2017 (PI)
Incyte Corporation

Enhancing Collectin Medicated Defense Against Influenza
08/11/2011 - 06/30/2015 (PI)
5R01 HL069031-12

Development of Novel Immunotherapy for Influenza Virus Infection
09/01/2007 - 08/31/2013 (PI)
Mass General Hosp NIH-NIAID

Collectins and Innate Defense against Inhaled Pathogens
09/01/2009 - 08/31/2012 (PI)
Trustees of Boston University NIH-NIAID

Collectins and Innate Defense against Inhaled Pathogens
09/30/2009 - 08/31/2011 (PI)
Trustees of Boston University NIH-NIAID

Collectin-Mediated Defense Against Influenza
04/01/2006 - 08/10/2011 (PI)
5 R01 HL069031-09

Innate Immunity in the Clearance of Influenza A Virus Ifected Apoptotic Cells
09/25/2007 - 08/31/2010 (PI)
Mass General Hosp NIH-NIAID

Novel Genetically Targeted Antiviral Agents
07/01/2005 - 06/30/2007 (PI)
Harvard Medical School NIH-NIAID

Showing 10 of 11 results. Show All Results

Yr Title Project-Sub Proj Pubs
2016 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-15 31
2014 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-13 31
2013 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-12 31
2012 Enhancing Collectin Mediated Defense Against Influenza 5R01HL069031-11 31
2011 Enhancing Collectin Mediated Defense Against Influenza 2R01HL069031-10 31
2010 Collectin-Mediated Defense Against Influenza 5R01HL069031-09 31
2009 Collectin-Mediated Defense Against Influenza 5R01HL069031-08 31
2008 Collectin-Mediated Defense Against Influenza 5R01HL069031-07 31
2007 Collectin-Mediated Defense Against Influenza 5R01HL069031-06 31
2006 Collectin-Mediated Defense Against Influenza 2R01HL069031-05A1 31
Showing 10 of 26 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. De Luna X, Hartshorn KL. Influenza Casts a Lung Shadow. Am J Pathol. 2017 Apr; 187(4):697-699. PMID: 28222276; DOI: 10.1016/j.ajpath.2017.01.007;.
  2. Elias R, Karantanos T, Sira E, Hartshorn KL. Immunotherapy comes of age: Immune aging & checkpoint inhibitors. J Geriatr Oncol. 2017 May; 8(3):229-235. PMID: 28223073; DOI: 10.1016/j.jgo.2017.02.001;.
  3. Chua MM, Ortega CE, Sheikh A, Lee M, Abdul-Rassoul H, Hartshorn KL, Dominguez I. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. Pharmaceuticals (Basel). 2017 Jan 28; 10(1).View Related Profiles. PMID: 28134850; DOI: 10.3390/ph10010018;.
  4. Phull P, Quillen K, Hartshorn KL. Acute Oxaliplatin-induced Hemolytic Anemia, Thrombocytopenia, and Renal Failure: Case Report and a Literature Review. Clin Colorectal Cancer. 2016 Nov 23.View Related Profiles. PMID: 27989485; DOI: 10.1016/j.clcc.2016.11.005;.
  5. White MR, Tripathi S, Verma A, Kingma P, Takahashi K, Jensenius J, Thiel S, Wang G, Crouch EC, Hartshorn KL. Collectins, H-ficolin and LL-37 reduce influence viral replication in human monocytes and modulate virus-induced cytokine production. Innate Immun. 2017 Jan; 23(1):77-88.View Related Profiles. PMID: 27856789; DOI: 10.1177/1753425916678470;.
  6. Shashar M, Siwak J, Tapan U, Lee SY, Meyer RD, Parrack P, Tan J, Khatami F, Francis J, Zhao Q, Hartshorn K, Kolachalama VB, Rahimi N, Chitalia V. c-Cbl mediates the degradation of tumorigenic nuclear ß-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors. Oncotarget. 2016 11 01; 7(44):71136-71150.View Related Profiles. PMID: 27661103; DOI: 10.18632/oncotarget.12107;.
  7. Lee SY, Sissoko M, Hartshorn KL. Update on the Management of Pancreatic Cancer in Older Adults. Curr Oncol Rep. 2016 Oct; 18(10):60. PMID: 27492426; DOI: 10.1007/s11912-016-0547-4;.
  8. Chelimeda S, Bejarano T, Lowe R, Soliman M, Zhao Q, Hartshorn KL. Long-Term Survival after Resection of Lung Metastases from Hepatocellular Cancer: Report of a Case and Review of the Literature. Case Rep Oncol. 2016 Sep-Dec; 9(3):559-564.View Related Profiles. PMID: 27790121.
  9. Hsieh IN, Hartshorn KL. The Role of Antimicrobial Peptides in Influenza Virus Infection and Their Potential as Antiviral and Immunomodulatory Therapy. Pharmaceuticals (Basel). 2016; 9(3).View Related Profiles. PMID: 27608030; DOI: 10.3390/ph9030053;.
  10. Khatri K, Klein JA, White MR, Grant OC, Leymarie N, Woods RJ, Hartshorn KL, Zaia J. Integrated Omics and Computational Glycobiology Reveal Structural Basis for Influenza A Virus Glycan Microheterogeneity and Host Interactions. Mol Cell Proteomics. 2016 Jun; 15(6):1895-912.View Related Profiles. PMID: 26984886; DOI: 10.1074/mcp.M116.058016;.
Showing 10 of 147 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 147 publications over 32 distinct years, with a maximum of 11 publications in 2012

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Gastrointestinal cancer
Innate Immunity
Contact for Mentoring:

650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map

Hartshorn's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department